SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

SANTA CRUZ BIOTECHNOLOGY, INC.

PRAME (h3): 293T Lysate: sc-129539

BACKGROUND

Several tumor-associated antigen families, such as MAGE, GAGE, PRAME and BAGE, are of particular interest in tumor immunology because their expression, with exception of testis and fetal tissues, seems to be restricted to tumor cells. The MAGE, BAGE and GAGE genes code for distinct antigens that are recognized by autologous cytolytic T lymphocytes. Many of these antigens represent suitable targets for tumor immunotherapy, since their expression in human melanoma cells is common and highly specific. PRAME (preferentially expressed antigen of melanoma) is a melanoma antigen recognized by cytotoxic T cells (CTLs) and is expressed in a variety of cancer cells, including leukemic cells. The PRAME gene is expressed at a high level in a very large fraction of tumors, such as melanomas, non small-cell lung carcinomas, sarcomas, head and neck tumors and renal carcinomas. Therefore, PRAME is a candidate for tumor immunotherapy, even though it is expressed at low levels in certain normal tissues.

REFERENCES

1. Li, J., Yang, Y., Fujie, T., Baba, K., Ueo, H., Mori, M. and Akiyoshi, T. 1996. Expression of BAGE, GAGE, and MAGE genes in human gastric carcinoma. Clin. Cancer Res. 2: 1619-1625.
2. Dalerba, P., Ricci, A., Russo, V., Rigatti, D., Nicotra, M.R., Mottolese, M., Bordignon, C., Natali, P.G. and Traversari, C. 1998. High homogeneity of MAGE, BAGE, GAGE, tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: implications for protocol design of therapeutic antigen-specific vaccination strategies. Int. J. Cancer 77: 200-204.
3. van Baren, N., Chambost, H., Ferrant, A., Michaux, L., Ikeda, H., Millard, I., Olive, D., Boon, T. and Coulie, P.G. 1998. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br. J. Haematol. 102: 1376-1379.
4. Pold, M., Zhou, J., Chen, G.L., Hall, J.M., Vescio, R.A. and Berenson, J.R. 1999. Identification of a new, unorthodox member of the MAGE gene family. Genomics 59: 161-167.
5. Matsushita, M., Ikeda, H., Kizaki, M., Okamoto, S., Ogasawara, M., Ikeda, Y. and Kawakami, Y. 2001. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br. J. Haematol. 112: 916-926.

CHROMOSOMAL LOCATION

Genetic locus: PRAME (human) mapping to 22q11.22.

PRODUCT

PRAME (h3): 293T Lysate represents a lysate of human PRAME transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

APPLICATIONS

PRAME (h3): 293T Lysate is suitable as a Western Blotting positive control for human reactive PRAME antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.